CoChat

Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders

Open access
Menke, Andreas · 2018 · Pharmacogenomics and Personalized Medicine

The DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.

Abstract

Mental disorders account for around one-third of disability worldwide and cause enormous personal and societal burden. Current pharmacotherapies and nonpharmacotherapies do help many patients, but there are still high rates of partial or no response, delayed effect, and unfavorable adverse effects. The current diagnostic taxonomy of mental disorders by the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases relies on presenting signs and symptoms, but does not reflect evidence from neurobiological and behavioral systems. However, in the last decades, the understanding of biological mechanisms underlying mental disorders has grown and can be used for the development of precision medicine, that is, to deliver a patient-tailored individual treatment. Precision medicine may incorporate genetic variants contributing to the mental disorder and the response to pharmacotherapies, but also consider gene ¥ environment interactions, blood-based markers, neuropsychological tests, data from electronic health records, early life adversity, stressful life events, and very proximal factors such as lifestyle, nutrition, and sport. Methods such as artificial intelligence and the underlying machine learning and deep learning approaches provide the framework to stratify patients, initiate specific tailored treatments and thus increase response rates, reduce adverse effects and medical errors. In conclusion, precision medicine uses measurable health parameters to identify individuals at risk of a mental disorder, to improve the diagnostic process and to deliver a patient-tailored treatment. Keywords: precision medicine, personalized medicine, biomarker, mental health, depression, childhood trauma, FKBP5, machine learning

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/pgpm.s146110

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Situations of patients with mental disorders are depicted. Notes: (A) Current situation: patients are evaluated by a clinician who stratifies the patients using the diagnostic taxonomy of DSM-5 or ICD-10; then, first-line treatment is initiated according to the diagnosis. Treatment is usually associated with a high rate of nonresponse. (B) Future situation: precision medicine guides the tailored approach for each individual patient with a mental disorder. Patients are evaluated possibly by systems employing machine learning methods that consider genetic and other biomarkers derived from blood, neuropsychological tests, or imaging and then stratified by biological subgroups/endophenotypes. Specific treatment algorithms are initiated according to the biological subgroup. Abbreviations: DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases.
Figure 1 Situations of patients with mental disorders are depicted. Notes: (A) Current situation: patients are evaluated by a clinician who stratifies the patients using the diagnostic taxonomy of DSM-5 or ICD-10; then, first-line treatment is initiated according to the diagnosis. Treatment is usually associated with a high rate of nonresponse. (B) Future situation: precision medicine guides the tailored approach for each individual patient with a mental disorder. Patients are evaluated possibly by systems employing machine learning methods that consider genetic and other biomarkers derived from blood, neuropsychological tests, or imaging and then stratified by biological subgroups/endophenotypes. Specific treatment algorithms are initiated according to the biological subgroup. Abbreviations: DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 181 references

Research works printed but not linked: 3

  1. [15]15. Wium-Andersen IK, Vinberg M, Kessing LV, McIntyre RS. Personal- ized medicine in psychiatry. Nord J Psychiatry. 2017;71(1):12-19.
  2. [113]113. Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychot- ics. Can J Psychiatry. 2014;59(2):76-88.
  3. [128]128. Yu S-H, Liu S-K, Lin K-M. Psychopharmacology across cultures. In: Bhugra D, Bhui K, editors. Textbook of Cultural Psychiatry. 1st ed. Cambridge, UK: Cambridge University Press; 2007:402-413.

Cited by

See all 44

Metadata

Authors
Menke, A.
Affiliations
University of Würzburg (DE)
Corresponding author
Menke, Andreas
Venue
Pharmacogenomics and Personalized Medicine
Published
2018-11
Volume
Volume 11
Pages
211-222
ISSN
1178-7066 (ISSN-L)
OpenAlex
W2900736680
Cited by
41
References
184
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 11 · 2020: 11 · 2019: 5
FWCI
0.79
Type
journal article
Language
en
Open access
Locations
  • Pharmacogenomics and Personalized Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
precision medicine, precision psychiatry, mental illness, pharmacotherapy response, biomarkers, genetic variants, gene-environment interaction, machine learning, artificial intelligence, depression, childhood trauma, FKBP5, electronic health records, neuropsychological assessment, childhood adversity, adverse drug reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.